FDC Limited Submits Quarterly Dematerialization Compliance Certificate for Q4 FY26

1 min read     Updated on 10 Apr 2026, 01:23 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

FDC Limited filed its mandatory quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26, covering dematerialization activities for the quarter ended March 31, 2026. Company Secretary Varsharani Katre submitted the certificate to BSE and NSE on April 10, 2026, with confirmation from registrar MUFG Intime India Private Limited regarding proper handling of securities transactions during the quarter.

powered bylight_fuzz_icon
37353181

*this image is generated using AI for illustrative purposes only.

FDC Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI's depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company filed its certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 on April 10, 2026. Company Secretary and Legal Head Varsharani Katre digitally signed and submitted the document to both BSE Limited and National Stock Exchange of India.

Filing Details: Information
Quarter Ended: March 31, 2026
Filing Date: April 10, 2026
Regulation: SEBI Regulation 74(5)
Authorized Signatory: Varsharani Katre, Company Secretary
Membership Number: FCS 8948

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as LINK Intime India Private Limited, serves as FDC Limited's Registrar and Share Transfer Agent. The registrar issued a confirmation certificate dated April 8, 2026, verifying compliance with dematerialization procedures during the quarter.

The registrar confirmed that securities received from depository participants for dematerialization were properly processed and that all security certificates were handled according to prescribed timelines. Ashok Shetty, Senior Vice President of Corporate Registry at MUFG Intime India, signed the confirmation certificate.

Corporate Information

FDC Limited operates from its registered office at FDC House, located in the Dalia Industrial Estate, Oshiwara Village, Andheri West, Mumbai. The company maintains its stock exchange listings with scrip code 531599 on BSE and symbol FDC on NSE.

Corporate Details: Information
BSE Scrip Code: 531599
NSE Symbol: FDC
Registered Office: Mumbai, Maharashtra
Registrar: MUFG Intime India Private Limited

This quarterly filing demonstrates FDC Limited's adherence to SEBI's regulatory framework governing the handling of dematerialized securities, ensuring transparency in share transfer operations and maintaining compliance with depositories regulations.

Historical Stock Returns for FDC

1 Day5 Days1 Month6 Months1 Year5 Years
-1.56%+2.91%+11.61%-16.37%-16.06%+19.62%

Will FDC Limited's consistent regulatory compliance improve its ESG ratings and attract more institutional investors?

How might the registrar's name change from LINK Intime to MUFG Intime India impact FDC's share transfer operations going forward?

Could FDC's strong compliance track record position it favorably for potential inclusion in SEBI's new regulatory sandbox programs?

FDC Limited Updates Board Committees and Re-designates Managing Director

2 min read     Updated on 20 Mar 2026, 07:51 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

FDC Limited announced comprehensive board changes including the appointment of CA Kishore Saletoe as Additional Independent Director and detailed reconstitution of Audit, Nomination & Remuneration, and CSR committees. The company also re-designated Mr. Mohan Chandavarkar as Chairman & Managing Director effective April 1, 2026.

powered bylight_fuzz_icon
35372299

*this image is generated using AI for illustrative purposes only.

FDC Limited announced significant board changes during its meeting held on March 18, 2026, including the appointment of a new independent director and reconstitution of key board committees. The pharmaceutical and chemicals manufacturer communicated these developments to stock exchanges under Regulation 30 of SEBI Listing Regulations, followed by detailed committee composition updates on March 20, 2026.

Director Transition and New Appointment

The board noted the cessation of CA Uday Kumar Gurkar's second term as Independent Director, which will conclude at the close of business hours on March 31, 2026. Based on the recommendation of the Nomination & Remuneration Committee, the board approved the appointment of CA Kishore Saletoe (DIN: 01705850) as Additional Independent Director.

Parameter: Details
Effective Date: April 1, 2026
Term Duration: 5 years
Term End Date: March 31, 2031
Approval Required: Shareholder approval through postal ballot

New Director's Professional Background

CA Kishore Saletoe brings over 30 years of diverse experience across globally renowned corporations, including the Tata Group, ITC Ltd., Hughes Corporation, and Bharat Forge. His expertise spans high-stakes mergers & acquisitions, joint ventures, and international expansions across sectors such as electric vehicles, real estate, infrastructure, and telecommunications.

Key highlights of his professional achievements include:

  • Demonstrated ability to deliver consistent shareholder value and operational efficiency
  • Experience leading large global teams and partnering with C-suite executives, investors, and regulators
  • Deep commitment to corporate governance, ethical leadership, and sustainable growth
  • Recipient of the prestigious CII CFO Award in 2022 for excellence in financial leadership

CA Kishore Saletoe is not related to any directors, key managerial personnel, promoters, or promoter group members of the company.

Board Committee Reconstitution

Effective April 1, 2026, the company reconstituted three key committees with updated member compositions:

Audit Committee

Position: Name Designation
Chairperson: CA Vijay Maniar Non-Executive Independent Director
Member: Mr. Mohan A. Chandavarkar Managing Director
Member: CA Vijay N Bhatt Non-Executive Independent Director
Member: CA Kishore M. Saleto Non-Executive Independent Director

Nomination and Remuneration Committee

Position: Name Designation
Chairperson: Dr. Mahesh Bijlani Non-Executive Independent Director
Member: CA Vijay Maniar Non-Executive Independent Director
Member: CA Vijay N Bhatt Non-Executive Independent Director

Corporate Social Responsibility Committee

Position: Name Designation
Chairperson: Mr. Mohan Chandavarkar Managing Director
Member: Mr. Ashok Chandavarkar Executive Director
Member: Ms. Nomita Chandavarkar Non-Executive Director
Member: Dr. Charuta Mandke Non-Executive Independent Director

Leadership Re-designation

Following the completion of CA Uday Kumar Gurkar's tenure as Independent Director and Chairman of the Board, Mr. Mohan Chandavarkar will be re-designated as Chairman & Managing Director with effect from April 1, 2026. This change consolidates leadership roles within the organization's management structure.

Shareholder Approval Process

The board approved seeking shareholder approval for CA Kishore Saletoe's appointment as Independent Director through a postal ballot process. The company stated that detailed information regarding the postal ballot would be communicated in due course.

The initial board meeting commenced at 11:00 a.m. and concluded at 2:40 p.m. (IST) on March 18, 2026. Company Secretary & Legal Head Varsharani Katre signed both regulatory filings, ensuring compliance with SEBI Listing Regulations.

Historical Stock Returns for FDC

1 Day5 Days1 Month6 Months1 Year5 Years
-1.56%+2.91%+11.61%-16.37%-16.06%+19.62%

How might CA Kishore Saletoe's M&A expertise influence FDC's future acquisition strategy in the pharmaceutical sector?

What impact could the consolidation of Chairman and Managing Director roles have on FDC's corporate governance structure and investor confidence?

Will FDC leverage the new director's electric vehicle and infrastructure experience to diversify beyond pharmaceuticals and chemicals?

More News on FDC

1 Year Returns:-16.06%